April 19, 2018 09:35 AM EDT
Financing

In knock­out IPO of­fer­ings, Mor­phoSys and Sur­face On­col­o­gy haul com­bined $316M in up­sized deals

Brittany Meiling

Two biotechs new to Nas­daq sparked more in­vestor in­ter­est than orig­i­nal­ly ex­pect­ed Wednes­day, haul­ing up­sized IPOs that are yet an­oth­er in­di­ca­tion of the in­dus­try’s rip …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times